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Translating the concept of peptide labeling with
5-deoxy-5-[18F]fluororibose into preclinical practice:
18F-labeling of Siglec-9 peptide for PET imaging of
inflammation†
Xiang-Guo Li,*ab Anu Autio,b Helena Ahtinen,b Kerttuli Helariutta,c
Heidi Liljenbäck,bd Sirpa Jalkanen,e Anne Roivainen*bd and Anu J. Airaksinen*c
Peptide glycosylation with 5-deoxy-5-[18F]fluororibose was trans-
lated into preclinical settings. The novel 18F-labeled Siglec-9
peptide was produced using an automated synthesis procedure.
The 18F-labeled Siglec-9 peptide showed favorable binding in the
animal model of inflammation in vivo.
Positron emission tomography (PET) is a sensitive and non-
invasive in vivo molecular imaging modality. Fluorine-18 (18F)
has favorable physical properties to generate high-resolution
PET images and consequently 18F-labeled compounds are the
most used tracers in clinical PET. Among the short-lived radio-
nuclides, the physical half-life of 18F (T1/2 = 109.7 minutes)
allows multi-step synthesis of tracers for the same-day use in
hospitals.1 Versatile fluorinating agents have been developed
for the synthesis of fluorine containing pharmaceuticals.1
However, only a small proportion of the existing fluorination
methods have been (or can be) translated into radiosynthesis of
18F-labeled compounds for preclinical and clinical applications.1a
This is especially true in the case of 18F-labeled biomolecules,
e.g. peptides, proteins and antibodies. Although many strate-
gies for 18F-labeling of peptides and proteins have shown some
promise during the last two decades, only a few have proved
amenable for routine large scale production for clinical use.
Oxime formation between an aldehyde (or a ketone) and an
aminooxy-functionalized compound is a classical and favorable
reaction in bioconjugation due to the high chemoselectivity.
Indeed, oxime formation has been successfully applied for the
production of [18F]fluciclatide (GE Healthcare) starting from
4-[18F]fluorobenzaldehyde ([18F]FBA). [18F]Fluciclatide is one of
the few 18F-labeled peptide tracers currently in clinical use.1b
Among the 18F-labeled aldehydes, [18F]FBA is probably the most
frequently used prosthetic group for peptide labeling. However,
[18F]FBA is volatile requiring additional measures to ensure
radiosafety and to reduce radioactive emission during the
production. The attachment of [18F]FBA may cause increased
lipophilicity, resulting in altered pharmacokinetics in vivo.1b
In addition to [18F]FBA, aldehydes 1–5 have recently been
developed for peptide labeling (Fig. 1, [a]).1b,2
It has been well documented that glycosylation may confer
favorable characteristics to peptide tracers for in vivo imaging.
The incorporation of a galactose fragment into the RGD peptide
has generated a very valuable peptide tracer, [18F]galacto-RGD.
So far, most of the published clinical PET imaging data con-
cerning 18F-labeled peptides has actually been generated using
this tracer. However, the synthesis procedure of [18F]galacto-
RGD is rather complex and is a major challenge for its wide-
spread use.3 As 2-deoxy-2-[18F]fluoroglucose ([18F]FDG, Fig. 1,
[b]) is available in virtually every PET radiochemistry lab, it is an
excellent concept to use [18F]FDG for peptide and protein
labeling.4 [18F]FDG is an aldose and has an open chain aldehyde
Fig. 1 18F-Labeled prosthetic groups for oxime formation.18F-Fluorinated
sugars are presented in their cyclic forms.1b,2
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form in solution.1b However, the conjugation between [18F]FDG
and aminooxy-functionalized peptides generally needs elevated
temperature and low pH and forms a complex product profile.1b,4b
Very recently, it has been discovered that 5-deoxy-5-[18F]fluoro-
ribose ([18F]FDR, Fig. 1, [b]) conjugates to peptides much more
efficiently than [18F]FDG does.5 Although we were able to produce
[18F]FDR in large scale in an automated procedure, we were not
able to perform the conjugation step efficiently enough for
preclinical PET studies. Furthermore, the quality of radiolabeled
peptides was not acceptable (e.g. low chemical purity) for in vivo
animal studies. Thus, peptide glycosylation with [18F]FDR
remained at a conceptual stage with respect to preclinical and
clinical utilities. In this communication, we report the trans-
lation of [18F]FDR-based bench chemistry into practical pre-
clinical use, and exemplify this utility on PET imaging of
vascular adhesion protein 1 (VAP-1), which is a promising
new target protein for PET imaging of inflammation.
In the previous work, [18F]FDR was prepared in high radio-
chemical purity (>98%) from precursor 6 (Scheme 1, [a]), and
the synthesis was scaled up to 4 GBq of radioactivity. However,
chemical purity of the synthesized [18F]FDR was not optimal
and the final product contained ribose in a mM-range, originat-
ing from precursor 6. Subsequently, only a small proportion of
the obtained [18F]FDR (8–20 MBq) was conjugated to model
peptides. In the presence of an appropriate amount of peptides
(e.g. at 23 mM of concentration), the conjugation reached
completion in 10 minutes in sodium acetate buffer (pH 4.6)
at rt.5 Scaling up the conjugation reaction was hampered due to
the high ribose content of the produced [18F]FDR. When
starting with 100 MBq-4 GBq of [18F]FDR, only 5% conversion
yields were achieved in an hour, even at high concentrations of
peptide (e.g. 40 mM). Since only nano- or picomoles of non-
carrier added and high specific radioactivity [18F]FDR was used,
the ribose was present in the conjugation mixture in a large
excess. Its presence as a competing aldehyde source resulted
in the inefficient conjugation of [18F]FDR (Scheme 1, [b]).
This prompted us to derive a strategy to produce [18F]FDR free
of ribose ([18F]FDR 8, Scheme 1, [a]). After the fluorination of
precursor 6 with K18F-K222, intermediate 7 was isolated using a
preparative HPLC column. The method gave an excellent
separation between the starting material 6 (retention time =
10.6 min) and intermediate 7 (retention time = 4.9 min) in a
short HPLC protocol. Thus, the synthesis procedure was not
significantly prolonged. The HPLC analysis of the isolated 7
proved the success of the intermediate purification step (ESI†).
After the acid-catalyzed hydrolysis of 7, [18F]FDR 8 was obtained
in high radiochemical purity (>98%). Subsequently, the pH of
[18F]FDR 8 solution was adjusted to 4.6 at which the efficiency
of peptide conjugation was optimal. The total preparation time
of the high purity [18F]FDR 8 was typically 85 min starting from
end-of-bombardment (EOB), including a concentration step of
the [18F]FDR solution before the conjugation reaction. In addi-
tion to 6, 1,2,3-tri-O-acetyl-5-O-tosyl ribose (AcRib, ESI†) was
tested as a precursor to produce [18F]FDR 8. Unfortunately, only
residual amount of [18F]FDR 8 was obtained from AcRib. In this
respect, compound 6 was a very applicable precursor in radio-
synthesis (n = 40). The next step was to prepare VAP-1 targeting
[18F]FDR-Siglec-9 peptide for in vivo imaging of inflammation
in rats (Scheme 1, [a] and [c]). VAP-1 is a 90 kDa glycoprotein
and is a unique target in inflammation.6 Inflammation is
highly relevant in major diseases including cancer, diabetes,
obesity and Alzheimer’s disease.6b In endothelial cells, VAP-1
stays in the intracellular storage granules under normal
physiological conditions. Upon inflammation, VAP-1 relocates
rapidly to the endothelial cell surface. This makes VAP-1 an
ideal target for diagnostic imaging of inflammation. Recently,
it has been discovered that sialic acid-binding Ig-like lectin 9
(Siglec-9) is a leukocyte ligand of VAP-1 and 68Ga-labeled
Siglec-9 motif peptide can be used as a PET tracer for in vivo
imaging of inflammation and cancer.7 Accordingly, peptide 9
(ESI†) was designed in order to enable conjugation to [18F]FDR
8 in this work.
In general, oxime formation is not the most efficient
chemical reaction and the substrates need to be used at
relatively high concentrations in order to reduce the reaction
time. Specific radioactivity of the cyclotron produced 18F is high
and the amount of the synthesized [18F]FDR 8 is in a nano- to
picomolar level. Following the reported conjugation procedure,5
the initial tests for the synthesis of [18F]FDR-Siglec-9 peptide
were carried out in sodium acetate buffer (pH 4.6, 90 mM) at rt.
However, the concentration of peptide 9 used (2.1 kDa) had to
be at over 15 mM (32.2 mg ml1), which was absolutely not
applicable. In a previous study, aniline was used to catalyze the
oxime formation between [18F]FBA and leptin.8 Accordingly, we
tested aniline-catalysis in the conjugation reactions between
5-deoxy-5-fluororibose ([19F]FDR) and 9 (Table 1). Being the
‘‘cold’’ counterpart of [18F]FDR 8, [19F]FDR was used to prepare
[19F]FDR-Siglec-9, which was needed as a reference in radio-
synthesis of [18F]FDR-Siglec-9. In anilinium buffer (0.3 M,
pH 4.6), the conjugation efficiency was dramatically enhanced
(Table 1, entries 1 and 2). Aniline has been proposed to catalyze
oxime formation with a rapid transimination mechanism.1b














































3684 Chem. Commun., 2013, 49, 3682--3684 This journal is c The Royal Society of Chemistry 2013
(0.6 mg ml1) and the conversion was 95% in 10 min at rt. The
concentration of the anilinium buffer also had an influence on
the conjugation efficiency (entries 2–4). Our results together
with the previous work demonstrated that aniline-catalyzed
oxime formation is chemoselective in the presence of any
amino acid side chain from all the 20 standard amino acids
under 18F-labeling conditions.8
A general challenge in developing peptide PET tracers is to
isolate the labeled products (e.g. [18F]FDR-Siglec-9) from their
unlabeled peptide precursors (e.g. 9). The possible residual
peptide precursors may compete with the tracer on binding
to the target protein or even saturate the target to be imaged.
Bearing this in mind, we developed a reproducible HPLC
method for efficient separation of [18F]FDR-Siglec-9 from 9 in
a preparative scale (ESI†). Finally, [18F]FDR-Siglec-9 was pre-
pared from the conjugation of [18F]FDR 8 to 9 (0.3 mM) in
anilinium buffer (pH 4.6) at rt and the conversion was 50–60%
in 10 min. The final product was isolated by HPLC with high
radiochemical purity (>98%). The amount of the peptide pre-
cursor 9 was under the detection limit of the UV-detection.
The total synthesis time was typically 120 minutes and the
decay-corrected radiochemical yield was 27% starting from
18F-fluoride (EOB). The two HPLC-purifications were well inte-
grated in the protocol and were performed with remote-control.
Both radiation exposure and radioactive emission were mini-
mal. The synthesis was scaled up to 1.1 GBq of the final product
[18F]FDR-Siglec-9. The specific radioactivity was 36–43 GBq mmol1
at the end-of-synthesis (EOS) (ESI†). [18F]FDR-Siglec-9 was
formulated in phosphate-buffered saline (PBS) for intravenous
injection. In PBS, [18F]FDR-Siglec-9 was stable for >4 hours and
thus suitable for in vivo imaging studies. The [18F]FDR-Siglec-9
(18.3  5.1 MBq) was intravenously injected into rats having
sterile, turpentine oil induced inflammation.7 Dynamic PET
imaging lasting for 1 hour was performed by using a High
Resolution Research Tomograph (Siemens). The inflammation
focus on the right shoulder area of the rats (n = 8) was clearly
visualized (Fig. 2). The target-to-muscle ratio was 9 : 1. The
observed liver uptake and rapid excretion through kidneys
to the urine were in line with our previous studies with
[68Ga]-DOTA-Siglec-9.7 Very importantly, bones were not visua-
lized, which was an indication that there was no in vivo defluori-
nation of the 18F-label on the prosthetic group [18F]FDR 8.
In conclusion, we have successfully translated [18F]FDR-based
oxime formation into the production of [18F]FDR-Siglec-9 peptide
for preclinical use. [18F]FDR-Siglec-9 has been produced in high
radiochemical quality and sufficient specific radioactivity facili-
tating in vivo PET imaging of experimental inflammation.
Further development of the tracer for clinical use is warranted.
[18F]FDR-conjugation is independent of peptide sequence and
the whole synthesis procedure can be automated. Thus,
[18F]FDR-based glycosylation should be generally applicable in
the development of peptide PET tracers.
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Table 1 The influence of aniline on conjugation efficiency of [19F]FDR to peptide
9 in 10 min of reaction (pH 4.6, rt)
Entry
Concentration of
[19F]FDR and 9a (mM) Buffer (M)
Conversionb
(%)
1 0.3 Sodium acetate (0.3) 5
2 0.3 Anilinium acetate (0.3) 95
3 0.3 Anilinium acetate (0.2) 89
4 0.3 Anilinium acetate (0.05) 63
5 0.1 Anilinium acetate (0.3) 48
a The two reagents were used in equal amounts. b Conversions were
determined using HPLC.
Fig. 2 Representative sagittal (left), transaxial (middle) and coronal (right)
multiplane PET images of [18F]FDR-Siglec-9 biodistribution in a rat. The images
are summation from 10–60 min post-injection.
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